Medical Therapy. Pharmacokinetics and Pharmacology

Inhalable Nitric Oxide Delivery Systems for Pulmonary Arterial Hypertension Treatment

Yoogyeong Oh, Kyungtae Park, Sungwon Jung, Moonhyun Choi, Taihyun Kim, Yoojin Kim, Yoojin Lee, Jae Young Choi, Yang-Hee Kim, Se Yong Jung, Jinkee HongYonsei University College of Medicine. University of Southampton.Republic of Korea and United Kingdom SmallSmall 2023; DOI: 10.1002/smll.202308936 AbstractPulmonary arterial hypertension (PAH) is a severe medical condition characterized by elevated blood pressure in the […]

Inhalable Nitric Oxide Delivery Systems for Pulmonary Arterial Hypertension Treatment Read More »

Multi-dose enteral L-citrulline administration in premature infants at risk of developing pulmonary hypertension associated with bronchopulmonary dysplasia

Candice D. Fike, Judy L. Aschner, Charul Avachat, Angela K. Birnbaum, Catherine M. T. SherwinUniversity of Utah Health. Albert Einstein College of Medicine. Hackensack Meridian School of Medicine. University of Minnesota. Wright State University Boonshoft School of Medicine.United States Journal of PerinatologyJ Perinatol 2023; DOI: 10.1038/s41372-023-01809-y AbstractObjective: Information is needed to guide the design of randomized controlled

Multi-dose enteral L-citrulline administration in premature infants at risk of developing pulmonary hypertension associated with bronchopulmonary dysplasia Read More »

Serum Levels After Everolimus-Stent Implantation and Paclitaxel-Balloon Angioplasty in an Infant with Recurrent Pulmonary Vein Obstruction After Repaired Total Anomalous Pulmonary Venous Connection

Matthias J. Muller, Ulrich Krause, Thomas Paul, Heike E. SchneiderGeorg-August-University Göttingen.Germany Pediatric CardiologyPediatr Cardiol 2011; 32: 1036-1039DOI: 10.1007/s00246-011-0054-1 AbstractEverolimus-eluting stents and paclitaxel-coated balloons are used in the interventional treatment of coronary artery disease in adults to reduce the restenosis rate and in small-vessel disease. Both substances are released into the circulation. We report systemic drug exposure

Serum Levels After Everolimus-Stent Implantation and Paclitaxel-Balloon Angioplasty in an Infant with Recurrent Pulmonary Vein Obstruction After Repaired Total Anomalous Pulmonary Venous Connection Read More »

The Anti-Inflammatory Effects and Clinical Potential of Dexmedetomidine in Pulmonary Arterial Hypertension

Yohei Yamaguchi, Susumu Hosokawa, Go Haraguchi, Yusuke Kajikawa, Makito Sakurai, Taku Ishii, Noboru Ando, Tomohiro Morio, Shozaburo Doi, Tetsushi FurukawaTokyo Medical and Dental University. Saitama Children’s Medical Center. National Hospital Organization Disaster Medical Center. Japan Journal of Pharmacology and Experimental TherapeuticsJ Pharmacol Exp Ther 2023; 385: 88-94DOI: 10.1124/jpet.122.001399 AbstractA pathogenic aspect of pulmonary arterial hypertension (PAH) is the aberrant pulmonary arterial smooth muscle cell

The Anti-Inflammatory Effects and Clinical Potential of Dexmedetomidine in Pulmonary Arterial Hypertension Read More »

Histone deacetylase inhibitors synergize with sildenafil to suppress purine metabolism and proliferation in pulmonary hypertension

Hui Zhang, Angelo D’Alessandro, Min Li, Julie A. Reisz, Suzette Riddle, Akshay Muralidhar, Todd Bull, Lan Zhao, Evgenia Gerasimovskaya, Kurt R. StenmarkUniversity of Colorado School of Medicine.  Imperial College London. United States and United Kingdom Vascular PharmacologyVasc Pharmacol 2023; 149: DOI: 10.1016/j.vph.2023.107157 AbstractRationale: Sildenafil, a well-known vasodilator known to interfere with purinergic signaling through effects on cGMP,

Histone deacetylase inhibitors synergize with sildenafil to suppress purine metabolism and proliferation in pulmonary hypertension Read More »

Pharmacotherapy for Pulmonary Hypertension in Infants with Bronchopulmonary Dysplasia: Past, Present, and Future

Candice D. Fike, Judy L. AschnerUniversity of Utah Health. Joseph M. Sanzari Children’s Hospital at Hackensack University.United States PharmaceuticalsPharmaceuticals 2023; 16: DOI: 10.3390/ph16040503 AbstractApproximately 8-42% of premature infants with chronic lung disease of prematurity, bronchopulmonary dysplasia (BPD), develop pulmonary hypertension (PH). Infants with BPD-PH carry alarmingly high mortality rates of up to 47%. Effective PH-targeted pharmacotherapies

Pharmacotherapy for Pulmonary Hypertension in Infants with Bronchopulmonary Dysplasia: Past, Present, and Future Read More »

Development and Optimization of Sildenafil Orodispersible Mini-Tablets (ODMTs) for Treatment of Pediatric Pulmonary Hypertension Using Response Surface Methodology

Ahmed Alalaiwe, Mohammad A. Alsenaidy, Ziyad S. Almalki, Mohamed H. FayedPrince Sattam Bin Abdulaziz University. King Saud University. Prince Sattam Bin Abdulaziz University. Fayoum University. Saudi Arabia PharmaceuticsPharmaceutics 2023; 15: DOI: 10.3390/pharmaceutics15030923 AbstractThe availability of age-appropriate oral dosage forms for pediatric patients has remained a challenge. Orodispersible mini-tablets (ODMTs) are a promising delivery system for pediatric

Development and Optimization of Sildenafil Orodispersible Mini-Tablets (ODMTs) for Treatment of Pediatric Pulmonary Hypertension Using Response Surface Methodology Read More »

Physiologically based pharmacokinetic modelling of treprostinil after intravenous injection and extended-release oral tablet administration in healthy volunteers: An extrapolation to other patient populations including patients with hepatic impairment

Xuemei Wu, Xiaohan Zhang, Ruichao Xu, Imam Hussain Shaik, Raman VenkataramananUniversity of Pittsburgh School of Pharmacy. Fujian Medical University Union Hospital. University of Virginia. University of Pittsburgh School of Medicine.United States and China British Journal of Clinical PharmacologyBrit J Clin Pharmacol 2022; 88: 587-599DOI: 10.1111/bcp.14966 AbstractAims: Pulmonary arterial hypertension (PAH) is characterized by increased pulmonary arterial pressure,

Physiologically based pharmacokinetic modelling of treprostinil after intravenous injection and extended-release oral tablet administration in healthy volunteers: An extrapolation to other patient populations including patients with hepatic impairment Read More »

Oral hymecromone decreases hyaluronan in human study participants

Joelle I. Rosser, Nadine Nagy, Riya Goel, Gernot Kaber, Sally Demirdjian, Jamie Saxena, Jennifer B. Bollyky, Adam R. Frymoyer, Ana E. Pacheco-Navarro, Elizabeth B. Burgener, Jayakumar Rajadas, Zhe Wang, Olga Arbach, Colleen E. Dunn, Anissa Kalinowski, Carlos E. Milla, Paul L. BollykyStanford University. UCSF School of Pharmacy. Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität Zu Berlin

Oral hymecromone decreases hyaluronan in human study participants Read More »

Implications for the metabolic fate of oral glutamine supplementation within plasma and erythrocytes of patients with sickle cell disease: A pharmacokinetics study

Claudia R. Morris, Frans A. Kuypers, Robert Hagar, Sandra Larkin, Lisa Lavrisha, Augusta Saulys, Elliott P. Vichinsky, Jung H. SuhEmory University School of Medicine and Children’s Healthcare of Atlanta. UCSF-Benioff Children’s Hospital Oakland.United States Complementary Therapies in MedicineComplement Ther Med 2022; 64: DOI: 10.1016/j.ctim.2022.102803 AbstractObjectives: L-Glutamine is FDA-approved for sickle cell disease (SCD), yet the mechanism(s)-of-action are

Implications for the metabolic fate of oral glutamine supplementation within plasma and erythrocytes of patients with sickle cell disease: A pharmacokinetics study Read More »

Scroll to Top